Lobbying disclosures · Lobbying report
LLY: second_quarter 2026 lobbying report
Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. Issues related to drug compounding.
Follow LLY- Became public
- Jul 12, 2026, 8:52 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 6:29 PM EST
Why this is connected
Legal-name match: ELI LILLY AND COMPANY is ELI LILLY & Co (https://www.sec.gov/Archives/edgar/data/59478/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $80,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/d9d1e129-63f6-4be4-9b77-5e233acd0a15/","filing_uuid":"d9d1e129-63f6-4be4-9b77-5e233acd0a15","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/d9d1e129-63f6-4be4-9b77-5e233acd0a15/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-12T20:52:17-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":55430,"url":"https://lda.gov/api/v1/clients/55430/","client_id":55430,"name":"ELI LILLY AND COMPANY","general_description":"American pharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Alzheimer's Disease. Anti Obesity Medication.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker","new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie","new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":"Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid","new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee","new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. Issues related to drug compounding.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":109746,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"UEHLECKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Price change after we could observe it
+0.38% LLY
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in LLY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 10, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Oct 20, 2026 · disclosed Nov 10, 2026
Traded 9 days before earnings - Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Jul 1, 2026 · disclosed Aug 7, 2026
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Bought Eli Lilly and Company LLY
$1K–$15K · Traded Jan 2, 2026 · disclosed Aug 7, 2026 · filed 217 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
Sold Eli Lilly and Company LLY
$1K–$15K · Traded Dec 2, 2025 · disclosed Aug 7, 2026 · filed 248 days later
Committee overlap: Energy and CommerceGot $1K from the company’s PAC - Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Sold (full) Eli Lilly and Company LLY
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jul 17, 2026$1K–$15K
Rep. Dan Newhouse (R-WA-4)
Sold (partial) Eli Lilly and Company LLY
$1K–$15K · Traded Jul 10, 2026 · disclosed Jul 17, 2026 · Spouse
- Jul 2, 2026$50K–$100K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Eli Lilly and Company LLY
$50K–$100K · Traded Jun 10, 2026 · disclosed Jul 2, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.